MannKind Corporation (NASDAQ:MNKD) had its price objective reduced by Cowen and Company from $5.50 to $5.00 in a report released on Wednesday,Stock Ratings News reports. Analysts at Piper Jaffray downgraded shares of MannKind Corporation (NASDAQ:MNKD) from a neutral rating to an underweight rating in a research note on Monday. MannKind Corporation (NASDAQ:MNKD) stock performance was -0.86% in last session and finished the day at $6.93. Traded volume was 26.46million shares in the last session and the average volume of the stock remained 10.08million shares. The beta of the stock remained 1.48. MannKind Corporation (NASDAQ:MNKD) insider ownership is 0.60%.

Gilead Sciences Inc (NASDAQ:GILD) CEO John C. Martin sold 140,625 shares of the company’s stock in a transaction that occurred on Tuesday, April 1st. The stock was sold at an average price of $73.26, for a total transaction of $10,302,187.50. Gilead Sciences, Inc. (NASDAQ:GILD) rose 0.05 percent to $74.00 Thursday on volume of 15.99million shares. The intra-day range of the stock was $72.79 to $75.18. Gilead Sciences, Inc. (NASDAQ:GILD) has a market capitalization of $113.80billion.

Ariad Pharmaceuticals Inc (NASDAQ:ARIA) has been given an average recommendation of “Hold” by the twenty-four analysts that are currently covering the stock, American Banking & Market News reports. Three investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and six have assigned a buy rating to the company. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)’s stock on Apr 03, 2014 reported a decrease of -3.60% to the closing price of $7.77. Its fifty two weeks range is $2.15 -$23.00. The total market capitalization recorded $1.45billion. The overall volume in the last trading session was 12.48million shares. In its share capital, ARIA has 186.33million outstanding shares.

CytRx Corporation (NASDAQ:CYTR) was up more than 6% after it said it will present positive preclinical results from an in vivo study of aldoxorubicin in an animal model of glioblastoma at a conference later this week. The biopharmaceutical company said data showed that aldoxorubicin significantly increased survival by almost 2.5 times compared to doxorubicin treatment in an in vivo xenograft tumor model employing growth of human glioblastoma multiforme (GBM) tumors in mouse brains. On Thursday, shares of CytRx Corporation (NASDAQ:CYTR) advanced 3.67% to close the day at $3.95. Company return on investment (ROI) is -257.90% and its monthly performance is recorded as -33.50%. CytRx Corporation (NASDAQ:CYTR) quarterly revenue growth is -42.75%.